江中药业(600750)：2025年收入符合预期 利润超预期

Core Viewpoint - The company forecasts a revenue of 4.22 billion yuan for 2025, a year-on-year decline of 5%, while the net profit attributable to shareholders is expected to be 906 million yuan, reflecting a year-on-year growth of 15% [1] Group 1: Financial Performance - The 2025 full-year revenue aligns with market expectations, while profits exceed expectations [2] - The slight decline in revenue is primarily attributed to a weak macro consumption environment affecting the OTC business [2] - The company aims to enhance brand building and optimize its cost structure to improve profitability [2] Group 2: Strategic Initiatives - The company has changed its name to Huaren Jiangzhong Pharmaceutical Co., Ltd., which is expected to strengthen brand recognition and market influence [2] - The management team from Huaren Jiangzhong is likely to further integrate into the listed company, optimizing group management levels [2] - The company plans to focus on three main business areas: strengthening OTC, developing health consumer products, and expanding prescription drugs [2] Group 3: Profit Forecast and Valuation - Revenue forecasts for 2025 and 2026 have been adjusted downwards by 6% to 4.22 billion yuan and 4.51 billion yuan, respectively, while net profit forecasts have been increased by 4% and 6% to 906 million yuan and 1.01 billion yuan [3] - The company maintains an outperform rating, with a target price raised by 6% to 28.90 yuan, indicating a potential upside of 23.3% [3]